[Elsevier] Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

jakir_ete_ruet Post time 3 day(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-09-16 04:37
Reward100points

journal:European Urology

Authors:Elizabeth R. Plimack; Thomas Powles; Viktor Stus; Rustem Gafanov; Dmitry Nosov; Tom Waddell; Boris Alekseev; Frédéric Pouliot; Bohuslav Melichar; Denis Soulières; Delphine Borchiellini; Raymond S. McDermott; Ihor Vynnychenko; Yen-Hwa Chang; Satoshi Tamada; Michael B. Atkins; Chenxiang Li; Rodolfo Perini; L. Rhoda Molife; Jens Bedke; Brian I. Rini

Published date:2023-11-

DOI:10.1016/j.eururo.2023.06.006

PDF link:https://www.sciencedirect.com/sc ... 302283823029019/pdf

Article link:https://doi.org/10.1016/j.eururo.2023.06.006



Article Source:Elsevier BV。



Remark:
User 'pbunny', don't upload anything.

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
malassaf Post time 3 day(s) ago | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Senior Member
  • post

  • reply

  • points

    151324


Daily Top Contributors

Return to the list